BioMarin Pharmaceutical Inc. BMRN
Set alert
At close
Pre-market · Nov 2, 4:22 AM ET
- YTD
- -1.55%
- 1 year
- +12.71%
- Open
- 58.39
- Prev close
- 57.49
- Mkt cap
- 11.33B
- Vol
- 2.27M
- Avg vol
- 2.25M
- EPS
- 0.37
- P/E
- 158.13
- Div yield
- 0.00%
More statistics
- Low
- 57.86
- High
- 59.37
- Forward P/E
- 9.12
- Beta
- 0.21
- Short ratio
- 5.25
- Inst. own
- 103.27%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 2, 2026
- 50-d avg
- 60.80
- 200-d avg
- 58.42
- 1y target
- 91.56
News
2 days ago defenseworld.net
BioMarin Pharmaceutical (NASDAQ:BMRN) Share Price Crosses Above Two Hundred Day Moving Average – Here’s Why
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN - Get Free Report)'s share price passed above its 200-day moving average during trading on Friday. The stock has a 200-day moving average of $58.44 and…
-
3 days ago benzinga.com
BioMarin Pharmaceutical Enters License Agreement With GC Biopharma And Hanmi Pharm To Develop And Commercialize Its HM15421/GC1134A Investigational Long-Acting Enzyme Replacement Therapy For Fabry Disease; Company To Pay $70M Up Front, With Partners Eligible For Up To $405M In Milestones
HM15421/GC1134A is a human recombinant alpha-galactosidase A (a-Gal A) enzyme therapy currently being studied in a Phase 1/2 clinical trial in people living with Fabry disease and has the potential…
3 days ago prnewswire.com
BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry Disease
Agreement grants BioMarin worldwide rights (excluding Korea) to HM15421/GC1134A, a long-acting, subcutaneous, clinical-stage enzyme replacement therapy for Fabry disease BioMarin will make an upfront…
6 days ago prnewswire.com
BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ET
SAN RAFAEL, Calif., Oct. 26, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a…
1 week ago defenseworld.net
Quadrant Capital Group LLC Makes New $564,000 Investment in BioMarin Pharmaceutical Inc. $BMRN
Quadrant Capital Group LLC bought a new stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) during the undefined quarter, according to its most recent filing with the SEC. The fund bought…
-
1 week ago benzinga.com
Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $122
Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price target from $124 to $122.
-
1 week ago benzinga.com
Cantor Fitzgerald Reiterates Overweight on BioMarin Pharmaceutical, Maintains $86 Price Target
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and maintains $86 price target.
-
2 weeks ago benzinga.com
Barclays Maintains Overweight on BioMarin Pharmaceutical, Raises Price Target to $114
Barclays analyst Eliana Merle maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target from $111 to $114.
-
3 weeks ago benzinga.com
BioMarin Pharmaceutical To Present New Data From Studies Of VOXZOGO In Children With Achondroplasia And Hypochondroplasia And From Studies Of Investigational Long-Acting BMN 333 At American Society For Bone And Mineral Research Meeting; New Analysis Showcases Impact Of VOXZOGO In Foramen Magnum And Craniocervical Junction Growth
The data include encouraging new imaging results from a post-hoc analysis of a randomized, double-blind, placebo-controlled trial evaluating the effect of VOXZOGO on the growth of the foramen magnum…
-
1 month ago benzinga.com
BioMarin Pharmaceutical Presents New Efficacy Data On POMBILITI + OPFOLDA In Pompe Disease At 31st Annual Congress Of World Muscle Society; No New Safety Signals Identified
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced new data evaluating the efficacy and safety of POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) in late-onset Pompe disease…